Avecia
 | The topic of this article may not meet Wikipedia's general notability guideline. (September 2023) |
 | This article needs additional citations for verification. (September 2023) |
Avecia, a part of Nitto Denko Inc.,[1] is a private biotechnology company focused on the development and manufacture of novel medicines using biotechnology techniques. Avecia operates as a contract manufacturing organization (CMO), specializing in oligonucleotide production.[citation needed]
Avecia has two US FDA-audited facilities, one near Boston, MA, and the second in Cincinnati, OH. The combined capacity of these two sites allows Avecia to handle oligonucleotide programs from the pre-clinical through commercial stages. In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals.[citation needed]
References[edit]
- ^ http://www.nitto.com www.nitto.com